AI Article Synopsis
- The study compares the prognostic accuracy of mid-regional pro-A-type natriuretic peptide (MRproANP) and B-type natriuretic peptide (BNP) in hospitalized patients with acute decompensated heart failure (ADHF).
- Researchers analyzed data from 37 patients, noting that BNP showed a significant decrease in event-free patients, while MRproANP tended to increase in patients who experienced cardiovascular events.
- Both BNP and MRproANP displayed similar prognostic accuracy, but MRproANP's trend could simplify interpretation of patient outcomes.
Article Abstract
Background: Mid-regional pro-A-type natriuretic peptide (MRproANP) seems to be non-inferior compared to B-type natriuretic peptide (BNP) for heart failure diagnosis and prognosis; however, no previous studies have investigated the MRproANP in-hospital changes in prognostic role. This study aimed to compare the prognostic accuracy of BNP and MRproANP in-hospital changes in acute decompensated heart failure (ADHF) patients.
Methods: 37 patients with either admission/pre-discharge BNP and MRproANP data, were investigated. The combined endpoint was cardiovascular death/heart transplantation/readmission for HF.
Results: BNP and MRproANP had a median decrease of 55% [72;45] and 21% [40; 11] respectively in event-free patients; BNP decrease of 34% [48; 29] but MRproANP increase of 4% [-7; 25] in patients with cardiovascular events. Prognostic accuracy of deltaBNP and deltaMRproANP was similar.
Conclusions: MRproANP basically trends up in patients with worse outcome and decreases in event-free patients, likely leading to a simpler interpretation although the prognostic accuracy is similar for both peptides.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!